Health and Fitness Health and Fitness
Wed, January 5, 2011
Tue, January 4, 2011
Mon, January 3, 2011

LecTec Corporation Announces Rescheduled Trial Date


Published on 2011-01-04 03:00:17 - Market Wire
  Print publication without navigation


TEXARKANA, Texas--([ BUSINESS WIRE ])--LecTec Corporation (OTCBB:LECT) announced that in the patent infringement litigation entitled LecTec Corporation v. Chattem, Inc. et al. the parties met with the appointed judge for the United States District Court for the Eastern District of Texas. LecTec was informed at such hearing that due to a pending, unrelated, criminal matter, the trial date would be postponed from January 4, 2011 to Monday January 10, 2011.

"Unexpected timing conflicts can arise in a courta™s trial docket. Although we are disappointed at the delay, we are prepared for the trial."

Greg Freitag, LecTeca™s CEO stated: aUnexpected timing conflicts can arise in a courta™s trial docket. Although we are disappointed at the delay, we are prepared for the trial.a

About LecTec

LecTec is an intellectual property (aIPa) licensing and holding company with approximately $9.3M in cash at September 30, 2010. LecTec holds multiple domestic and international patents based on its original hydrogel patch technology and has also filed for a provisional patent forits hand sanitizer patch. The LecTec hydrogel patch technology allows for a number of potential applications, including its previously marketed TheraPatch® products, while its anti-microbial hand sanitizer patch is intended to be dry, thereby rendering the patch harmless in the event that it is licked, chewed, or exposed to the eye. An initial prototype of the hand sanitizer patch has been developed and LecTec intends to engage a strategic partner to complete its hand sanitizer patch development. Pursuit of manufacturing and marketing/co-marketing partners for products from LecTeca™s IP is also ongoing. LecTec has a licensing agreement (aNovartis Agreementa) with Novartis Consumer Health, Inc., which pays royalties to LecTec from time to time, within the terms of the Novartis Agreement, based upon a percentage of Novartisa™ net sales of licensed products. LecTec takes legal action as necessary to protect its IP and is currently involved in two patent infringement actions. Finally, LecTec is pursuing a merger/acquisition strategy with the intent to leverage its cash asset and improve shareholder value and liquidity. The Companya™s website is [ www.lectec.com ].

Cautionary Statements

This press release contains forwarda"looking statements concerning possible or anticipated future results of operations or business developments which are typically preceded by the words abelieves,a awants,a aexpects,a aanticipates,a aintends,a awill,a amay,a ashould,a or similar expressions. Such forward looking statements are subject to risks and uncertainties, which could cause results or developments to differ materially from those, indicated in the forwarda"looking statements. Such risks and uncertainties include, but are not limited to, the Companya™s dependence on royalty payments from Novartis Consumer Health, Inc., which is selling an adult vapor patch licensed by the Company, the Companya™s dependence on key personnel and Board of Director members, the Companya™s pending patent infringement litigation against Chattem, Inc. and Prince of Peace Enterprises, Inc., the issuance of new accounting pronouncements, information disseminated on internet message boards from posters expressing opinions that may or may not be factual, the availability of opportunities for license, sale or strategic partner agreements related to patents that the Company holds, limitations on market expansion opportunities, and other risks and uncertainties detailed from time to time in the Companya™s filings with the Securities and Exchange Commission, and particularly as described in the aRisk Factorsa included in our Form 10a"K for the year ended December 31, 2009.

Contributing Sources